MACOM Technology vs State Street SPDR S&P Biotech ETF — how do they compare? MACOM Technology trades at $330.06 (market cap $24.61B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: MACOM Technology is far larger — about 2.4× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 1,594,575). Which is the better fit depends on your goals — on Pluang, investors hold MACOM Technology for 6 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MTSI | XBI | |
|---|---|---|
Market Cap | $24.61B | $10.11B |
Volume | 1,594,575 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $409.68 | $169.55 |
52-Week Low | $122.18 | $104.99 |
Typical Hold Time | 6 Days | 38 Days |
Enterprise Value | $24.32B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
MACOM develops analog, radio frequency, microwave, and optical semiconductors. Its components are used in telecommunications, data centers, industrial systems, aerospace, and defense applications.
Read more on MTSI →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →